Measurement of antithrombin activity by thrombin-based and by factor Xa- based chromogenic substrate assays

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 2, 2000, Pages 127-135

  Beeck, H ^a   Nagel, D ^a   Pindur, G ^b   Scharrer, I ^c   Preiss, A ^a   Seiler, D ^a   Hellstern, P ^a  

^a Academic City Hospital   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antithrombin; Antithrombin deficiency; Chromogenic substrate assays; Factor Xa; Heparin; Lepirudin; Specificity; Thrombin

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; HEPARIN; HIRUDIN; LEPIRUDIN; THROMBIN; THROMBIN INHIBITOR;

ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; ASSAY; BLOOD DONOR; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELIABILITY;

EID: 0034005090     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200003000-00003     Document Type: Article

References (26)

1. 1. Lechner K, Kyrle PA. Antithrombin III concentrates - are they clinically useful? Thromb Haemost 1995; 73: 340-348.
2. 2. Baudo F, Caimi TM, deCataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24: 336-342.
3. 3. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
4. 4. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.
5. 5. Ødegård OR, Lie M, Abildgaard DU. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294.
6. 6. Abildgaard U, Lie M, Ødegård OR. Antithrombin (heparin cofactor) assay with 'new' chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553.
7. 7. Ødegård OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Thromb Res 1976; 5: 265-275.
8. 8. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169.
9. 9. Friberger P, Egberg N, Holmer E, Hellgren M, Blombäck M. Antithrombin assay - the use of human or bovine thrombin and the observation of a 'second' heparin cofactor. Thomb Res 1982; 25: 433-436.
10. 10. Gram J, Jespersen J. Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin III. Clin Chem 1989; 35: 52-55.
11. 11. Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69: 231-235.
12. 12. Tran TH, Duckert F. Influence of heparin cofactor II (HCII) on the determination of antithrombin III (AT). Thromb Res 1985; 40: 571-576.
13. 13. Conard J, Bara L, Horellou M, Samama MM. Bovine or human thrombin in amidolytic assays. Influence of heparin cofactor II. Thromb Res 1986; 41: 873-878.
14. 14. Tollefsen DM, Pestka CA. Heparin cofactor II in patients with disseminated intravascular coagulation and hepatic failure. Blood 1985; 66: 769-774.
15. 15. Bohner J, von Pape K, Blaurock M. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence. Thromb Haemost 1994; 71: 280-283.
16. 16. Laposata M, Green D, van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.
17. 17. Bland JM, Altman DG. Statistical methods assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310.
18. 18. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995; 346: 1085-1087.
19. 19. Ødegård OR, Fagerhol MK, Lie M. Heparin cofactor activity and antithrombin III concentration in plasma related to age and sex. Scand J Haematol 1976; 17: 258-262.
20. 20. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390.
21. 21. Zoldhelyi P, Webster WI, Fuster V, Grill DE, Gaspar D, Edwards SJ, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015-2022.
22. 22. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Sem Thromb Hemost 1996; 22: 197-202.
23. 23. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-925.
24. 24. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
25. 25. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042-1048.
26. 26. Weenink GH, Kahlé LH, Larnping RJ, Ten Cate JW, Treffers PE. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 1984; 63: 57-61.